On February 26, 2026, Johnson & Johnson (NYSE:JNJ) provided an update, reporting promising Phase 1b data for pasritamig, a ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, ...

TAIPEI, March 5, 2026 /PRNewswire/ -- Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) (stock code: 7427) announced that its independently developed novel epigenetic immunoactivator ...

Researchers engineer CAR-astrocytes to target and remove amyloid plaques in Alzheimer’s, showing a 50% reduction in brain ...

Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) (stock code: 7427) announced that its independently developed novel epigenetic immunoactivator GNTbm-38, with global rights for cancer ...

Company announces manufacturing readiness and financing extension ahead of first-in-human clinical studyLondon, United Kingdom, March 5, 2026, ...

Presented positive updated data from the ALLOHA™ Phase 1 heme trial at 67th American Society of Hematology (ASH) Annual Meeting and ...

February 2026 saw a major biopharma acquisition, four key buyouts, and licensing deals in antibodies, small molecules, and ...

Antengene grants UCB worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, targeting B cell-related autoimmune diseases.

Find out how immunotherapy can improve cancer treatment outcomes and the systemic barriers limiting its widespread use.

T Biosciences, an immunotherapy company changing the future of treatment for solid tumors and other immune-mediated diseases, today announced the appointment of Rebeca Villarreal-Barragan, MBA, as ...

Good morning, and welcome to the Rallybio Corporation conference call to discuss the merger of Rallybio and Candid Therapeutics. It is now my pleasure to turn the call over to Dr. Stephen Uden, ...